$15.6m for TriReme's third funding round:
This article was originally published in Clinica
Executive Summary
Pleasanton, California-based TriReme Medical has raised $15.6m in new capital to fund the development and ongoing clinical trials of its single-balloon bifurcation stent system. The series C financing came from lead investor Three Arch Partners and Adams Street Partners. TriReme said its device has a lower profile than standard bifurcation stent systems. In addition, the delivery system is the only one of its kind that allows the doctor to actively determine the orientation of the stent prior to deployment, thereby ensuring precise positioning.